Literature DB >> 9848705

Phenformin and lactic acidosis: a case report and review.

S C Kwong1, J Brubacher.   

Abstract

Phenformin was removed from the U.S. market 20 years ago because of a high incidence of lactic acidosis. Unfortunately, this medication is still available from foreign sources. Another biguanide, metformin, was reintroduced to the United States market for the treatment of diabetes. Biguanide-induced lactic acidosis should be included in the differential diagnosis of elevated anion gap metabolic acidosis. We present a case of phenformin-induced lactic acidosis in which we were consulted at the local poison control center. We also review its pathophysiology, presentation, and treatment. A review of the actions of phenformin illustrates the mechanism of pathology that may also occur with metformin. Risk factors for the development of lactic acidosis include renal deficiency, hepatic disease, cardiac disease, and drug interaction such as cimetidine.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9848705     DOI: 10.1016/s0736-4679(98)00103-6

Source DB:  PubMed          Journal:  J Emerg Med        ISSN: 0736-4679            Impact factor:   1.484


  17 in total

Review 1.  Metformin-associated lactic acidosis (MALA): case files of the Einstein Medical Center medical toxicology fellowship.

Authors:  Kathryn T Kopec; Michael J Kowalski
Journal:  J Med Toxicol       Date:  2013-03

Review 2.  Resveratrol, sirtuins, and the promise of a DR mimetic.

Authors:  Joseph A Baur
Journal:  Mech Ageing Dev       Date:  2010-02-26       Impact factor: 5.432

Review 3.  Mitochondria-Targeted Triphenylphosphonium-Based Compounds: Syntheses, Mechanisms of Action, and Therapeutic and Diagnostic Applications.

Authors:  Jacek Zielonka; Joy Joseph; Adam Sikora; Micael Hardy; Olivier Ouari; Jeannette Vasquez-Vivar; Gang Cheng; Marcos Lopez; Balaraman Kalyanaraman
Journal:  Chem Rev       Date:  2017-06-27       Impact factor: 60.622

Review 4.  Mitochondria-targeted metformins: anti-tumour and redox signalling mechanisms.

Authors:  Balaraman Kalyanaraman; Gang Cheng; Micael Hardy; Olivier Ouari; Adam Sikora; Jacek Zielonka; Michael Dwinell
Journal:  Interface Focus       Date:  2017-04-06       Impact factor: 3.906

Review 5.  Dissecting the Dual Role of AMPK in Cancer: From Experimental to Human Studies.

Authors:  Giorgia Zadra; Julie L Batista; Massimo Loda
Journal:  Mol Cancer Res       Date:  2015-05-08       Impact factor: 5.852

Review 6.  Still sour about lactic acidosis years later: role of metformin in heart failure.

Authors:  William Kuan; Craig J Beavers; Maya E Guglin
Journal:  Heart Fail Rev       Date:  2018-05       Impact factor: 4.214

Review 7.  Hepatic steatosis and type 2 diabetes mellitus.

Authors:  Jeanne M Clark; Anna Mae Diehl
Journal:  Curr Diab Rep       Date:  2002-06       Impact factor: 4.810

8.  Patterns of use of insulin-sensitizing agents among diabetic, borderline diabetic and non-diabetic women in the National Health and Nutrition Examination Surveys.

Authors:  Hind Beydoun; Vijaya Kancherla; Laurel Stadtmauer; May Beydoun
Journal:  Gynecol Endocrinol       Date:  2013-01-17       Impact factor: 2.260

9.  Direct effects of phenformin on metabolism/bioenergetics and viability of SH-SY5Y neuroblastoma cells.

Authors:  Fintan Geoghegan; Naomi Chadderton; G Jane Farrar; Daniela M Zisterer; Richard K Porter
Journal:  Oncol Lett       Date:  2017-09-14       Impact factor: 2.967

10.  Association of Metformin Use With Risk of Lactic Acidosis Across the Range of Kidney Function: A Community-Based Cohort Study.

Authors:  Benjamin Lazarus; Aozhou Wu; Jung-Im Shin; Yingying Sang; G Caleb Alexander; Alex Secora; Lesley A Inker; Josef Coresh; Alex R Chang; Morgan E Grams
Journal:  JAMA Intern Med       Date:  2018-07-01       Impact factor: 21.873

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.